A review of secondary coronary prevention with dipyridamole and aspirin.
A large number of placebo-controlled trials of antiplatelet drugs have been carried out. A summary of the results of AMIS, CDP, ISIS-2, PARIS I and II and the Antiplatelet Trialists' Collaboration is presented. It is concluded that two fatal events and three non-fatal events will be averted for every 100 patients given a 2-year course of antiplatelet agents, starting promptly after myocardial infarction.
Prentice
C R
CR
University Department of Medicine, General Infirmary, Leeds, UK.
D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D012307:Risk Factors
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin